Positioned to transform the HBV treatment landscape and address the HBV global market opportunity
Portfolio of assets combining multiple technologies aimed at curing HBV
Proven scientific leadership in antiviral and RNAi drug discovery and development
Arbutus Biopharma Corporation (NASDAQ: ABUS) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with complementary mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.
In addition to our HBV Assets, we have developed a proprietary delivery platform Lipid Nanoparticle (LNP), which is a proven delivery technology in RNA interference (RNAi) development.
Arbutus has a very broad HBV product pipeline against encompassing direct antiviral, host targeting and immune-based approaches, which include our lead RNAi asset ARB-1467, our next-generation RNAi agent ARB-1740, our capsid assembly inhibitor AB-423 and multiple pre-clinical assets.
